Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathology by Pritam Das et al.
Das et al. Molecular Neurodegeneration 2012, 7:39
http://www.molecularneurodegeneration.com/content/7/1/39RESEARCH ARTICLE Open AccessTransient pharmacologic lowering of Aβ
production prior to deposition results in
sustained reduction of amyloid plaque pathology
Pritam Das1*, Christophe Verbeeck1, Lisa Minter2, Paramita Chakrabarty3, Kevin Felsenstein3, Thomas Kukar4,
Ghulam Maharvi1, Abdul Fauq1, Barbara A Osborne2 and Todd E Golde3*Abstract
Background: Alzheimer’s disease (AD) is the leading cause of dementia among the elderly. Disease modifying
therapies targeting Aβ that are in development have been proposed to be more effective if treatment was initiated
prior to significant accumulation of Aβ in the brain, but optimal timing of treatment initiation has not been clearly
established in the clinic. We compared the efficacy of transient pharmacologic reduction of brain Aβ with a
γ-secretase inhibitor (GSI ) for 1–3 months (M) treatment windows in APP Tg2576 mice and subsequent aging of
the mice to either 15M or 18M.
Results: These data show that reducing Aβ production in a 2-3M windows both initiated and discontinued before
detectable Aβ deposition has the most significant impact on Aβ loads up to 11M after treatment discontinuation.
In contrast, initiation of treatment for 3M windows from 7-10M or 12-15M shows progressively decreasing efficacy.
Conclusions: These data have major implications for clinical testing of therapeutics aimed at lowering Aβ
production, indicating that; i) these therapies may have little efficacy unless tested as prophylactics or in the earliest
preclinical stage of AD where there is no or minimal Aβ accumulation and ii) lowering Aβ production transiently
during a critical pre-deposition window potentially provides long-lasting efficacy after discontinuation of the
treatment.
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Alzheimer’s disease (AD) is the leading cause of demen-
tia among the elderly. Numerous studies in humans have
demonstrated the sequential development of various
pathological features that characterize AD and the rela-
tionship of these pathologies to diagnosis of dementia
[1]. These studies support the amyloid cascade hypoth-
esis which posits that accumulation of Aβ aggregates
triggers a series of downstream pathologies that results
in clinical AD [2]. AD has recently been proposed to
have three pre-clinical stages, characterized in sequence* Correspondence: das.pritam@mayo.edu; tgolde@ufl.edu
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reproduction in any medium, provided the orby the development of Aβ pathology (stage 1), the pres-
ence of plaque pathology, neurofibrillary pathology and
initial evidence for neurodegeneration (stage 2), and fi-
nally by the presence of stage 2, pathologies plus evi-
dence for subtle cognitive decline (stage 3). This
progression likely occurs over a 10–20 year timeline [3].
The amyloid cascade hypothesis predicts that attenuat-
ing or preventing Aβ aggregation and accumulation will
attenuate or prevent the subsequent development of AD.
Strong experimental support for the amyloid hypothesis
has supported the rationale for many therapeutic
approaches targeting Aβ. Major investments have been
made to develop inhibitors or modulators of Aβ produc-
tion [4]. γ-secretase inhibitors (GSIs), β-secretase inhibi-
tors (BSIs) and γ-secretase modulators (GSMs) have
been or are currently being tested in human AD trials.
Both the GSM tarenflurbil (R-flurbiporfren), and the GSI
semagacestat, failed to show efficacy in phase III human. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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rently in early stage trials. Based on the clinical failures
of tarenflurbil and semagacestat as well as other anti-Aβ
therapies not targeting Aβ production but its aggrega-
tion or clearance, we and others have begun to question
whether targeting of Aβ in symptomatic AD may be a
futile endeavor [6].
Given the framework provided by the amyloid cascade
hypothesis, disappointing results from completed trials
of anti-Aβ therapies in patients with AD, and several but
limited preclinical studies supporting the concept that
when targeting Aβ “earlier is better” [7-9], we explored
the relationship between long-term efficacy with respect
to reducing amyloid loads and timing and duration of
Aβ lowering. In designing these studies, we were struck
by the parallels between Aβ accumulation in the mouse
brain and in vitro studies of Aβ aggregation. In vitro, Aβ
aggregates in a nucleation dependent polymerization re-
action, which exhibits three phases: a lag phase in which
nucleation occurs but not fibril formation, an exponen-
tial growth phase in which fibril formation and growth
occur rapidly, and a plateau phase where fibril growth
and formation slows [10]. Except for being more
extended in terms of time, studies in APP Tg2576 trans-
genic mice show that Aβ aggregation and accumulation
follows a similar course in the brain [11]. There is an ini-
tial lag phase where no Aβ aggregation and accumula-
tion occurs, followed by an exponential accumulation
phase, and finally when amyloid loads become AD-like,
the growth slows or plateaus (see Figure 1A). Given
these parallels, we tested the efficacy of transient lower-
ing of Aβ production in 1-3M treatment “windows” cor-
responding to these various phases of deposition using
the GSI LY-411,575 (LY) in APP Tg2576 mice. These
data show that GSI treatment during the pre-deposition
window (4-7M) before the early exponential phase of de-
position (7-10M) or late exponential phase (12-15M) has
by far the most efficacy in terms of reduction of plaque
loads at 15M of age.
Results and discussion
In vitro and in vivo dosing studies with Ly-411,575
Ly-411,575 is potent orally bioavailable γ-secretase in-
hibitor [12]. We synthesized large quantities for these
studies and then performed both in vitro and in vivo
studies to validate Ly-411,575 potency. The IC50 in cell
culture for LY-411,575 was between 1–3 nm (see Add-
itional file 1: Figure S1A). Six hours after a single IP
dose, Aβ40 levels are reduced by ~75% in the brain of
non-depositing Tg2576 mice (Additional file 1: Figure
S1B). Oral administration (10 mg/kg/day) administered
as a single dose reduces brain Aβ40 levels 24 hours
after the final dose (7 days) by ~65% (Additional file 1:
Figure S1C) and plasma Aβ40 by ~95% (Additional file 1:Figure S1D). Plasma Aβ levels are reduced more quickly
than brain levels following oral dosing with maximal in-
hibition seen after 3 days (Additional file 1: Figure S1D).
For long term in vivo mouse studies, we tested adminis-
tration of Ly-411,575 using various dosing strategies
and time points (Table 1). Oral administration (formu-
lated in rodent chow) continually for 2 weeks with either
- 1 mg/kg/day or 2.5 5 mg/kg/day reduced brain Aβ40
levels by ~50% and plasma Aβ40 by ~80%, without overt
toxicities ( Table 1). However, continuous oral dosing
(>2 weeks) using the higher dose of 5 mg/kg/day or
10 mg/kg/day resulted in overt toxicities in mice
(Table 1). Therefore, in all long term studies presented
in this manuscript, we have used the 2.5 mg/kg/day dose
formulated in rodent chow.
Transient Aβ reduction dramatically reduces the
subsequent accumulation of amyloid plaques
For these experiments, we transiently dosed Tg2576
mice with LY from 4-7M, 7-10M or 12-15M and aged
treated mice to 15M (see Figure 1B for experimental de-
sign). To confirm efficacy of LY in all groups, we mea-
sured plasma Aβ levels immediately after the last day of
treatment in sentinel mice and showed a similar reduc-
tion in plasma Aβ levels in all cohorts (Table 2). Follow-
ing sacrifice at 15M, levels of Aβ in the brain were
examined. The 4-7M LY treatment significantly reduced
Aβ deposition; plaque burden in the frontal cortex and
hippocampus was decreased by ~68% (Figure 1C) and
FA-solubilized brain Aβ levels were reduced by ~60%
(Figure 1D). The 7-10M LY treatment non-significantly
decreased Aβ plaque burden by ~19% compared to con-
trols (Figure 1C), whereas FA-solubilized Aβ levels were
reduced by ~34% (Figure 1D). The 12-15M GSI treat-
ment group had no significant effect on either plaque
burden or FA-solubilized Aβ levels (Figure 1C, D). We
further evaluated effect of the 4-7M LY treatment on
cored amyloid plaques and cerebral amyloid angiopathy
(CAA). Compared to untreated control mice, there were
significant reductions both in cored plaques in the
frontal cortex and hippocampus (~47% reduction) and
CAA in the leptomeninges (~41% reduction, Figure 2A,
B). To further determine whether the magnitude of the
effect diminished with further aging, we performed an
additional experiment, where we aged 4-7M LY treated
mice to 18M, and again we observed significantly
reduced Aβ plaque burden and FA-solubilized Aβ levels
(Figure 2C), demonstrating that the suppression of de-
position was maintained even up 11 months after treat-
ment was halted.
Because Aβ deposition in mice follows an exponential
course, we sought to determine how the observed reduc-
tions in Aβ accumulation correlate with Aβ accumula-
tion to untreated mice. We compared Aβ levels in the
Figure 1 Effects of LY window therapy on amyloid deposition. A. Time course of Aβ accumulation in Tg2576 mice. FA solubilized brain
Aβ42 +Aβ40 levels measured by ELISA are shown (n= 3–5 mice/age group). B. Schematic of the various transient LY dosing strategies. Dotted
lines represent the transient LY treatment time points. C. Aβ plaque burden analysis of treated cohorts compared to controls (*p< 0.05, ** ns,
ANOVA). D. Biochemical analyses (FA solubilized Aβ42 +Aβ40 levels) by ELISA showing Aβ levels. (*p< 0.05, **ns, ANOVA). E. Representative brain
sections stained with anti-Aβ mAb showing Aβ plaques at 15M of age in the LY treated cohorts. Scale bar = 100 μm.
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ging from 10–18 months and plotted the natural loga-
rithm transformed value of these against Aβ levels from
the 4-7M LY treated mice, aged to 15M and 18M
(Figure 2D). To minimize variance, we assayed all of the
samples in a single set of ELISA studies. This analysis
showed that the 4 -7M GSI treatment time frame “shifts”amyloid depositing by approximately 3 months, essen-
tially delaying Aβ accumulation by a time roughly
equivalent to the treatment window.
We next attempted to determine whether this 4-7M
narrow therapeutic “window” can be further refined. To
do this, we transiently dosed Tg2576 mice with LY for 1,
2 or 3M intervals between the 4-7M age time frame and
Table 1 Brain and plasma Aβ40 levels following in vivo GSI treatment in Tg2576 mice
Compound Strain
of Mice










LY-411, 575 Tg2576 Intraperitoneal 5 mg/kg 6 hrs 75% 92% No
10 mg/kg 6 hrs 77% 96% No
25 mg/kg 6 hrs 78% 92% No
LY-411, 575 Tg2576 Oral (Suspension in Kool-Aid) 10 mg/kg/day 1 Day 47% 70% No
3 Days 65% 86% No
7 days 75% 95% No
LY-411, 575 Tg2576 Oral (Formulated In Rodent Chow) 1 mg/kg/day 2 weeks 36% 67% No
2.5 mg/kg/day 2 weeks 51% 78% No
5 mg/kg/day 2 weeks 78% 91% Yes*
10 mg/kg/day 2 weeks 83% 95% Yes*
Tg2576 mice (3 months old) were dosed with GSI LY-411,575 using various routes, time points and indicated doses. After GSI treatment, groups of mice
(n =3/group) were sacrificed and mouse brains were harvested and extracted in 2% SDS. Brain and plasma Aβ40 levels were then measured by ELISA.
*Diarrhea and hair loss.
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cantly reduced in this second 4-7M LY cohort (~59%
reduction) at 15M of age compared to controls
(Figure 2E). Similarly, i) the 4-6M LY cohort showed a
significant reduction in Aβ levels (~51% reduction) and;
ii) the 4-5M LY group showed a modest but non-
significant reduction in Aβ levels (~ 24% reduction)
(Figure 2E). However, in the remaining 5-6M, 6-7M or
5-7M LY cohorts tested, none showed any significant
reductions in Aβ levels at 15M compared to controls
(Figure 2E). Since we show that the 4-7M LY “shifts”
amyloid deposition equivalently to the duration of
treatment, we wondered whether we will see a similar
shift in amyloid deposition in the shorter treatment
intervals examined that showed efficacy, e.g., in the 4-
5M and 4-6M cohorts. Again, we compared Aβ levels
in the brains of untreated Tg2576 mice from various
ages ranging from 10–15 months against Aβ levels
from the 4-5M, 4-6M, and 4-7M LY treated cohorts
aged to 15M (Figure 2F). This analysis seems to show
that the 4-5M GSI treatment “shifts” amyloid depositingTable 2 Plasma Aβ40 levels following transient GSI
treatment in Tg2576 mice
Treatment Time Treatment Groups Plasma Aβ40 (pM)
4-7 Month Ly-411,575 341.3 ± 20.1 (81%)
Control 1742.6 ± 103.5
7-10 Month Ly-411,575 327.5 ± 18.5 (79%)
Control 1520.7 ± 100.8
12-15 Month Ly-411,575 427.3 ± 31.4 (70%)
Control 1388.4 ± 223.2
Tg2576 mice were transiently dosed with GSI LY-411,575(2.5 mg/kg/day) at
indicated time points. After GSI treatment was discontinued (on last day of
treatment), plasma from groups of mice (n =3/group) was collected and
plasma Aβ40 levels were measured by ELISA.
-Numbers in parenthesis represent percent reduction in Aβ levels.by approximately 1 month, however, both the 4-6M and
4-7M treatment intervals essentially show a similar shift
in Aβ accumulation, namely by roughly 3 months
(Figure 2F). These data would suggest, at least within
the 4-7M time frame that we have studied, that the
4-6M age interval may play a critical role in the early
seeding phases of amyloid deposition. Additional studies,
using either earlier treatment times (e.g. starting at 3M
of age) or longer treatment intervals may be necessary to
fully appreciate the usefulness of this early “therapeutic
window” to achieve the best possible outcome on subse-
quent amyloid deposition.
Transient GSI does not permanently alter APP levels or
processing
To determine if the 4-7M LY treatment had long-
lasting effects on Aβ production or APP levels and
processing, we conducted a number of studies. We
measured plasma Aβ levels at termination of GSI treat-
ment and then determined how long before steady
state levels of Aβ were normalized. Plasma Aβ levels
were significantly lower immediately after treatment,
but returned to control levels between with 1–2 weeks
after treatment was halted (Figure 3A). We also mea-
sured levels of full-length APP and APP C-terminal
fragments (CTFs) in the brain at the end of the 4-7M
treatment and at 15M. Immediately following discon-
tinuation of treatment, APP levels were unchanged but
APP CTFs were increased (Figure 3B,D). However, at
15 months, there were no significant differences in full
length APP or CTFs (Figure 3C,D). Finally, as GSI
treatment has been shown to affect peripheral lympho-
cytes [13], we performed FACS analysis and quantified
both B and T cell numbers in the spleen after the 4–
7M LY transient treatment and at 15M. B and T cell
numbers were not affected (Figure 4A). However, when
Figure 2 Effects of LY window therapy on amyloid deposition. A. Quantitative burden analysis of cored amyloid deposits and CAA in the
4-7M LY treated group compared to controls. (*p< 0.05, Student’s t test). B. Representative brain sections stained with mAb 13.1.1 showing cored
plaque and CAA immune-reactivity at 15M in the brains of Control and 4-7M LY treated Tg2576 mice. Arrows indicate CAA in meningeal vessels.
Scale bar = 80 μm. C. Biochemical analyses of FA solubilized Aβ levels and plaque burden analysis from Tg2576 mice transiently dosed with LY
(2.5mpk/day) from 4-7M, and aged to 18M. (*p< 0.05, Student’s t test). Tg2576 mice (n= 5-6/group) were used, data represented is from one
independent experiment. D. Natural logarithm transformed Aβ values of untreated Tg2576 mice (at indicated ages) and Aβ levels from 4-7M LY
treatment measured at 15M and 18M of age. E. Biochemical analyses of FA solubilized Aβ levels of Tg2576 mice transiently dosed with LY
(2.5mpk/day) at 1, 2, and 3M intervals and then aged till 15M. (*p< 0.05, ANOVA). Tg2576 mice (n=5-8/group) were used, data represented is
from one independent experiment. F. Graph representing Aβ values of untreated Tg2576 mice (from indicated ages) and Aβ levels from 4-5M,
4-6M and 4-7M LY transient treatment measured at 15M. FA solubilized brain Aβ42 +Aβ40 levels measured by ELISA are shown.
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CD4+ T cells from the 4-7M LY treated cohort showed
a bias towards Th1 polarization with increased IFN-γ
secretion (a canonical Th1 cytokine) and concurrent
decreases in IL-4 levels (a signature Th2 cytokine),
which persisted even after the treatment was halted for
8 months (Figure 4B, C,). The significance of this long-
lasting effect on peripheral CD4+T cell immune
responses is not clear, but certainly warrants further
investigation.Conclusion
Our current data show that transiently lowering Aβ pro-
duction in Tg2576 mice during the pre-deposition “seed-
ing” phase has a major impact on subsequent Aβ
accumulation with the effect persisting for at least 11M.
Later treatment windows showed decreasing efficacy of
treatment. These current data have major implications
for trial design targeting Aβ production in humans. In-
deed, they would suggest that efficacy in terms of plaque



























































































Figure 3 Long term LY treatment does not permanently affect
APP levels or processing. A. Plasma Aβ40 levels by ELISA after
the end of 4–7M LY treatment, (7M), 1 week after termination
of treatment, and 2 weeks after termination of treatment. B.
Representative anti-APP CT20 immunoblot shows APP levels and
accumulation of CTFs after 4-7M LY treatment (tested at 7M). C.
Representative anti-APP CT20 immunoblot showing full length APP
levels and CTFs after transient 4-7M LY treatment (tested at 15M). D.
Quantitative intensity analysis of anti-CT20 immuno-reactive full
length APP and APP CTF protein levels normalized to actin.
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exponential phase of deposition. A recent report [14]
using passive immunotherapy provided more limited evi-
dence that a similar effect may be observed with anti-Aβ
passive immunotherapy initiated during the early depos-
ition phase persisting for 3 months after discontinuationof treatment. Given the plethora of anti-Aβ therapies
currently in development, it will be essential to deter-
mine for each modality whether efficacy is both main-
tained after discontinuation and similarly influenced by
timing of the treatment.
The near equivalence of the delay in subsequent de-
position to the length of the treatment window during a
pre-deposition phase suggests that the GSI treatment
from 4-7M alters or reverses seeding of Aβ. Indeed,
there are no plaques forming during this period of time.
Future studies will be necessary to determine the exact
mechanisms by which lowering Aβ in this window alters
subsequent deposition. As even in vitro detection of Aβ
nucleation relies on indirect assays that have limited
sensitivities, these studies will likely require a better
understanding of nucleation and better assays to detect
it. Developing such assays will be critical as direct trans-
lation of these studies would be facilitated by defining
the equivalent window in humans. Regardless of mech-
anism, these preclinical window therapy studies have
major implications regarding the potential of prophylac-
tic therapy targeting Aβ production in humans. Not only
do these data suggest that prophylactic therapy in the
appropriate window will be more efficacious then initiat-
ing therapy in individuals with any preexisting Aβ path-
ology, but they suggest that such therapy, even if
discontinued might delay subsequent onset AD by a
time roughly equivalent to the time of treatment.
Methods
Tg2576 mice
APP Tg2576 mice were generated, maintained and geno-
typed as described previously [7]. All animal husbandry
procedures performed were approved by the Mayo
Clinic Institutional Animal Care and Use Committee in
accordance with National Institutes of Health guidelines.
All animals were housed three to five to a cage and
maintained on ad libitum food and water with a 12 h
light/dark cycle.
LY-411, 575
LY-411, 575 (LY) was synthesized at the Mayo Clinic
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Figure 4 Effect of LY treatment on peripheral immune cells. A.
Distribution of splenic B cell (IgD, CD19) and T cells (CD4 and CD8)
from control and Tg2576 mice treated with LY (4-7M). Percent
positive cells are shown (n= 4 mice/group). B and C. IFN production
(B) and IL-4 production (C) by CD4+ T cells from LY (4-7M) treated
Tg2576 mice and untreated control mice were measured by ELISA.
Equal numbers of purified, splenic CD4+ T cells (pooled from n =4
mice/group) were used. ND=not determined.
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nously incorporated into Harlan Teklad 7012 kibble
chow by Research Diets, Inc, New Jersey). Based upon
dietary consumption at this age, these diets were
designed to deliver 2.5 mg of LY on average per day.
Tg2575 mice (n = 7-15/group/experiment) were transi-
ently treated with LY chow at 1, 2 or 3 months interval
(between 4–7 months of age), from 7–10 months of age
and from 12–15 months of age. Untreated control mice
from each age group were as aged and used for analysis.
Groups of mice (n =3) were sacrificed immediately after
the end of each treatment time-point to access efficacy
of LY inhibition. After treatment was halted, mice were
then aged till 15 months or 18 months of age and then
sacrificed for Aβ analysis. Chow consumption, general
health and body weight were monitored on a weekly
basis in all treatment groups.Biochemical Aβ ELISA assay
Snap-frozen hemi-forebrains from Tg2576 mice were
two-step sequentially extracted in 2% SDS buffer
followed by 70% formic acid (FA) as described pre-
viously [16]. Aβ levels from brain lysates or plasma
were the measured using sandwich ELISA techniques
as described previously [16] with end specific mAbs
2.1.3 (human Aβx-42 specific, Mayo) and mAb 13.1.1
(human Aβx-40 specific, Mayo) for capture and HRP-
conjugated mAb Ab5 (human Aβ1–16 specific, Mayo)
for detection.Immunohistological analysis
Sagittal sections of paraffin embedded sections were
used for analysis. Immunohistochemical staining was
done using pan-Aβ antibody (mAb 33.1.1; Mayo), mAb
13.1.1 (human Aβx-40 specific, binds cored plaques and
CAA; Mayo) as previously described [17]. Immunohisto-
chemically stained sections were captured using the
Scanscope XT image scanner (Aperio, Vista, CA, USA)
and analyzed using the ImageScope program. Aβ plaque
burden was then calculated using the Positive Pixel
Count program (Aperio). At least 5 sections/brain
30 μm apart, were used and averaged by a blinded obser-
ver to calculate plaque burden.Western blotting
2% SDS solubilized brain lysate samples were separated
on Bis-Tris 12% XT gels (Bio-Rad, Hercules, CA, USA)
and probed with the antibody CT20 (anti-APP C-
terminal 20 amino acid; 1:1000; P.D) and anti-actin
(1:1000; Sigma, St. Louis, MO, USA). Band intensity was
quantified using ImageJ software (National Institutes of
Health, Bethesda, MD, USA).
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Immuno-phenotyping
Single cell suspensions were prepared aseptically from
spleens from control or GSI -treated mice. CD4+ T cells
were positively selected using the BD-IMAG system and
CD4+DM particles (BD Biosciences, San Diego, CA),
according to the manufacturer’s directions. Twelve-well
tissue culture plates were precoated with anti-hamster Ig
(Sigma), then with antibodies specific for CD3E and
CD28. Equal numbers of cells (3x106) were added to
each well. For TH1 polarizing conditions, anti-IL4
(10μg/ml) plus IL-12 (1 ng/ml) was added to cul-
ture wells; for TH2 polarizing conditions, anti-IFNγ
(10μg/ml) plus IL-4 (1 ng/ml) was added to culture
wells. No additional reagents were added to cells cul-
tured under neutral conditions. After 24 hours, all wells
were pulsed with IL-2 (10 ng/ml). After 96 hours, super-
natants were collected and frozen at -80C until analyzed
by ELISA for cytokine secretion. IFNγ and IL-4 cytokine
secretion was measured using ELISA kits per manu-
factures instructions (BD Pharmingen). For cell sur-
face staining, approximately 1x106 cells (each antibody)
were stained with the following antibodies individually:
IgD-FITC, biotinylated anti-CD19 plus strep-PE, CD4-
FITC, CD8-PE (BD Pharmingen). Data were analyzed
using an LSRII flow cytometer (BD Biosciences) and
FACSDiva software for acquisition and analysis.
Statistics
All statistics were done using Graphpad Prism (Version
5.0). Comparisons of multiple groups were done by one-
way ANOVA followed by Tukey's post hoc testing. Com-
parisons between two groups were done by Student's
t test with Welch's correction for unequal variances
where appropriate.
Additional file
Additional file 1: Figure S1A Wild type APP overexpressing CHO cells
were treated with indicated concentrations of LY-411,575 overnight.
Conditioned media were then assayed for secreted Aβ40 by sandwich
ELISA. Figure S1B. Acute LY-411,575 treatment reduces Aβ40 levels in
brains of mice. Tg2576 mice (3 month old) were injected with LY-411,575
(5 mg/kg) intraperitoneally. Mice were sacrificed 6 hrs later and brain (2%
SDS solubilized) Aβ40 levels were measured ELISA.
(n=3 mice/group) Figure S1C, D. Tg2576 mice were dosed orally
(suspended in Kool-Aid) with LY-411,575 (10 mg/kg) for indicated times
and brain (2% SDS solubilized) Aβ40 levels (C) and plasma Aβ40 levels
(D) were measured by ELISA (n=3 mice/group).
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